Stocks and Investing Stocks and Investing
Thu, January 26, 2017
Wed, January 25, 2017
Tue, January 24, 2017
Mon, January 23, 2017

Kennen MacKay Initiated (BMRN) at Buy with Decreased Target to $107 on, Jan 23rd, 2017


Published on 2024-10-25 20:03:48 - WOPRAI, Kennen MacKay
  Print publication without navigation


Kennen MacKay of Credit Suisse, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Decreased Target from $111 to $107 on, Jan 23rd, 2017.

Kennen has made no other calls on BMRN in the last 4 months.



There are 3 other peers that have a rating on BMRN. Out of the 3 peers that are also analyzing BMRN, 2 agree with Kennen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Gena Wang of "Barclays" Downgraded from Buy to Hold and Decreased Target to $105 on, Tuesday, November 29th, 2016
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold on, Monday, November 7th, 2016


This is the rating of the analyst that currently disagrees with Kennen


  • Andrew Peters of "Deutsche Bank" Initiated at Strong Buy on, Thursday, November 3rd, 2016